Two RCTs exploring gynecological disturbances demonstrated greater improvements of dysmenorrhea (Cobellis et al., 2011) and pelvic pain (Cobellis et al., 2011; Tartaglia et al., 2015) among PEA-treated EMS (Cobellis et al., 2011) and primary dysmenorrhea (Tartaglia et al., 2015) patients compared to those on placebo, although indicating PEA inferiority to Cyclooxygenase-2 (COX-2) inhibitors (Cobellis et al., 2011). The gene discussed is PTGS2; the disease is Dysmenorrhea.